Pharma Dynamics announces commercial agreement with Creso Pharma for hemp oil-based Cannaqix®

South Africa’s leading provider of cardiovascular medicine, Pharma Dynamics, has announced the signing of a Commercial Term Sheet with Creso Pharma, a leading global provider of cannabis products headquartered in Australia.

 

The agreement affords Pharma Dynamics sole distribution rights of Creso’s organic, broad spectrum hemp oil nutraceutical, cannaQIX®10, across South Africa, Namibia, Botswana, Zimbabwe, Swaziland, Lesotho, Angola, Mozambique and Uganda.

 

The cannaQIX® range of products are hemp oil-based cannabidiol (CBD) nutraceuticals, which contain full spectrum organic hemp oil extracts with CBD, vitamins and zinc, aiming to reduce stress and to support mental and nervous functions.

Cannabidiol is one of many identified cannabinoids in cannabis plants that has been linked to improved anxiety symptoms, pain management, movement therapy and cognition.

The products are sugar-free and contain no Tetrahydrocannabinol (THC) – the principal psychoactive constituent of cannabis.

 

The standardised, user-friendly strength and formulation allows precise dosage control, ensuring a reliable and stable effects over several days. The cannaQIX® range has been developed to Good Manufacturing Practice standards and is produced in Switzerland by Creso’s partner, the Swiss-based food and pharma development company, Domaco (Dr. med Aufdermaur AG Domaco) to the highest Swiss quality with a “Swiss Made” label.

 

Pharma Dynamics CEO, Erik Roos, says that in line with the organisation’s ethos of increasing access to affordable, quality medication, it has identified Creso Pharma as its partner of choice to bring novel products to patients in South Africa.

“Creso Pharma is globally recognised as a leader in the production of cannabis products with distribution agreements already in various countries in Europe and the Asia-Pacific. The company cultivates its cannabis at its state-of-the-art Mernova Medical facility in Windsor, Nova Scotia, and its pharmaceutical leadership team ensures cutting edge science from research to develop of innovative cannabis and hemp-derived products. We hope that this agreement will form the foundation of a longstanding relationship as we grow our footprint of nutraceuticals into the scheduled market as well.”

 

Dr. Miri Halperin Wernli, Creso Pharma’s CEO and co-founder said that the evolving regulatory situation in South Africa is providing a solid foundation on which to build this close relationship with Pharma Dynamics, “We are encouraged to see a wide range of opportunities opening up to bring premium hemp oil nutraceutical products to customers in South Africa”.

About Creso Pharma & Domaco, Dr. med Aufdermaur AG

Creso Pharma 

Creso Pharma brings the best of cannabis to better the lives of people and animals. It adds pharmaceutical expertise and methodological rigor to the cannabis world and strives for the highest quality in its products. It develops cannabis and hemp-derived therapeutic, nutraceutical, and lifestyle products with wide patient and consumer reach for human and animal health. Creso Pharma uses GMP (Good Manufacturing Practice) development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids. To learn more please visit: www.cresopharma.com

Domaco, Dr. med Aufdermaur AG

Domaco, Dr. med Aufdermaur AG is a Swiss-based food and pharma development company that owns the rights to a number of innovative delivery systems used to administer active ingredients through galenic forms (a way of preparing and compounding medicines in order to optimise their absorption). To learn more, please visit:  www.domaco-pharma.com

Share this article